Details of the Drug

General Information of Drug (ID: DMACYW6)

Drug Name
NKTR-214
Synonyms bempegaldesleukin
Indication
Disease Entry ICD 11 Status REF
Melanoma 2C30 Phase 3 [1]
Drug Type
Recombinant protein
Cross-matching ID
UNII
BNO1JG5MZC
DrugBank ID
DB15140
TTD ID
D5ISZ1

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Interleukin 2 receptor beta (IL2RB) TT9721Y IL2RB_HUMAN Agonist [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Melanoma
ICD Disease Classification 2C30
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Interleukin 2 receptor beta (IL2RB) DTT IL2RB 7.52E-01 -0.06 -1.11
Interleukin 2 receptor beta (IL2RB) DTT IL2RB 1.96E-01 -4.70E-03 -0.01
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT03635983) A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma. U.S. National Institutes of Health.
2 Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy. Nat Commun. 2020 Jan 31;11(1):661.